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Abstract
Background: Nicotine replacement therapy (NRT) is the most common form of smoking cessation
pharmacotherapy and has proven efficacy for the treatment of tobacco dependence. Although expectations of
mild adverse effects have been observed to be independent predictors of reduced motivation to use NRT,
adverse effects associated with NRT have not been precisely quantified.
Objective: A systematic review and meta-analysis aimed to identify all randomized clinical trials (RCTs) of NRT
versus inert controls and all observational studies to determine the magnitude of reported adverse effects with
NRT.
Methods: Searches of 10 electronic databases from inception to November 2009 were conducted. Study selection
and data extraction were carried out independently in duplicate. RCTs were pooled using a random effects
method with Odds Ratio [OR] as the effect measure, while proportions were pooled from observational studies.
A meta-regression analysis was applied to examine whether the nicotine patch is associated with different adverse
effects from those common to orally administered NRT.
Results: Ninety-two RCTs involving 32,185 participants and 28 observational studies involving 145, 205 participants
were identified. Pooled RCT evidence of varying NRT formulations found an increased risk of heart palpitations and
chest pains (OR 2.06, 95% Confidence Interval [CI] 1.51-2.82, P < 0.001); nausea and vomiting (OR 1.67, 95% CI
1.37-2.04, P < 0.001); gastrointestinal complaints (OR 1.54, 95% CI, 1.25-1.89, P < 0.001); and insomnia (OR 1.42, 95%
CI, 1.21-1.66, P < 0.001). Pooled evidence specific to the NRT patch found an increase in skin irritations (OR 2.80,
95% CO, 2.28-3.24, P < 0.001). Orally administered NRT was associated with mouth and throat soreness (OR 1.87,
95% CI, 1.36-2.57, P < 0.001); mouth ulcers (OR 1.49, 95% CI, 1.05-2.20, P < 0.001); hiccoughs (OR 7.68, 95% CI,
4.59-12.85, P < 0.001) and coughing (OR 2.89, 95% CI, 1.92-4.33, P < 0.001). There was no statistically significant
increase in anxiety or depressive symptoms associated with NRT use. Non-comparative observational studies
demonstrated the prevalence of these events in a broad population.
Conclusion: The use of NRT is associated with a variety of side effects. In addition to counseling and medical
monitoring, clinicians should inform patients of potential side effects which are associated with the use of NRT
for the treatment of tobacco dependence.
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Smoking is the leading cause of preventable mortality
world wide[1]. One in every 2 long-term smokers will
die a smoking related death[2]. Stopping smoking has a
considerable impact on improving life expectancy, redu-
cing morbidity and reducing health care costs associated
with treating smoking related conditions[3].
Several pharmacological interventions to assist in
smoking cessation are available[4]. The most commonly
used formulation is nicotine replacement therapy
(NRT), frequently available over the counter (OTC).
NRT is currently recommended as a safe intervention to
general populations and higher-risk groups, including
pregnant and breastfeeding women, adolescents, and
smokers with cardiovascular disease[5]. NRT improves
cessation rates at one year by approximately 70% (odds
ratio [OR] 1.70, 95% Confidence Interval [CI] 1.55-1.88)
[4,6].
Available research suggests that smokers are less moti-
vated to use NRT if they expect that it will cause mild
adverse effects[7]. Published systematic reviews of NRT
have not explicitly synthesized the incidence of side
effects of NRT products. An understanding of the
nature and likelihood of the most common side effects
may help clinicians communicate to patients the bene-
fits and risks associated with their use of NRT. This
information may also improve selection of specific deliv-
ery mechanisms based upon patient history, which may
improve treatment adherence. While RCTs provide
strong information on causation of adverse events,
observational studies may report on associations or
hypotheses about more rare events. To determine the
frequency and incidence of adverse events associated
with NRT, we conducted a systematic review and meta-
analysis of RCT’s and observational studies of NRT in
any delivery formulation. Our clinical question is, in
patients receiving NRT for smoking cessation, compared
to inert controls, what is the incidence of adverse events
and what are those adverse events?
Methods
Eligibility criteria
We included RCTs of any duration beyond 4 weeks.
RCTs had to compare NRT with an inert control
(eg. placebo or standard of care). We chose 4 weeks to
include the timeframe of maximum nicotine withdrawal
symptoms so that adverse events may be differentiated
from withdrawal symptoms[8]. We additionally sought
out observational studies to examine the proportion of
events occurring[9]. We evaluated adverse effects
reported at any point in the duration of the studies. We
included any form of NRT delivery (i.e. lozenge, skin
patch, gum, nasal spray, inhaler, and tablet). We did not
examine efficacy in this analysis. We excluded post-hoc
analyses, maintenance therapy, or relapse prevention
studies.
Search strategy
In consultation with a medical librarian, we established
a search strategy. We searched independently, in dupli-
cate, the following 10 databases (from inception to
November 20, 2009): MEDLINE, EMBASE, Cochrane
CENTRAL, AMED, CINAHL, TOXNET, Development
and Reproductive Toxicology, Hazardous Substances
Databank, Psych-info and Web of Science. Given that
observational studies are poorly indexed in many data-
bases, we also searched databases that include the full
text of journals (ScienceDirect,a n dIngenta,i n c l u d i n g
articles in full text from approximately 1700 journals
since 1993)[10]. In addition, we searched the bibliogra-
phies of published systematic reviews and health tech-
nology assessments[4-6,11-16]. Searches were not
limited by language, sex or age.
Study selection
Two investigators (EM, PW) working independently, in
duplicate, scanned all abstracts and obtained the full
text reports of records indicating that the study was
either an RCT or observational study evaluating NRT
on the outcomes of interest. After obtaining full reports
of the candidate studies (either in full peer-reviewed
publication or press article) the same reviewers indepen-
dently assessed eligibility via full text review.
Data collection
Two reviewers (EM, PW) conducted data extraction
independently using a standardized pre-piloted form.
Reviewers collected information about the NRT inter-
vention tested, the population studied (age, sex, underly-
ing conditions), treatment dosages and dosing schedules,
the specific measurement of abstinence (prolonged or
point-prevalence), and the methods of biochemical con-
firmation. The reviewers extracted data on adverse
events characterized by the study authors as physical or
mental adverse events. Recognizing that adverse events
may include both physical and mental effects concomi-
tantly, we defined physical adverse events as effects con-
fined to physical parts of the body and mental adverse
events as symptoms accompanied by psychological con-
ditions. We characterized serious adverse events as
unexpected life-threatening events occurring during the
trial period. Ap r i o r i , we examined the follow life-threa-
tening adverse events: all-cause mortality, myocardial
infarction, all-cause strokes, incidence of all-cancers,
all-hospitalizations, suicidal ideation, depression, and
incidence of diabetes. Study quality evaluation included
general methodological reporting features including
allocation concealment, sequence generation, blinding
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loss to follow-up. In rating quality, failure to report a
quality component of study design (e.g. blinding) was
treated the same as not employing it. We entered the
data into an electronic database such that duplicate
entries existed for each study. When the two entries did
not match, we resolved differences through discussion
and consensus. In the absence of an inert control group,
we considered randomized NRT dosing studies to be
observational studies and collected data on proportion
of combined events. For cohort studies, we additionally
calculated events as proportions of events.
Data analysis
In order to assess inter-rater reliability on inclusion of
articles, we calculated the Phi statistic (j), which pro-
vides a measure of inter-observer agreement indepen-
dent of chance[17]. We calculated the Odds Ratios [OR]
and appropriate 95% Confidence Intervals [CIs] of out-
comes according to the number of events reported in
the original studies or sub-studies. Given that zero
events in one treatment arm prevents a useful ratio
from being developed, in circumstances of zero outcome
events in one arm of a trial, we added 0.5 to each arm,
as suggested by Sheehe[18]. We first pooled studies of
all NRT interventions versus all controls using the
DerSimonian-Laird random effects method[19], which
recognizes and anchors studies as a sample of all poten-
tial studies, and incorporates an additional between-
study component to the estimate of variability[20]. We
calculated the I
2 statistic for each analysis as a measure
of the proportion of the overall variation that is attribu-
table to between-study heterogeneity[21]. Given that we
are examining adverse events, interpreting heterogeneity
estimates can be challenging as even pooled analysis
with large heterogeneity may provide important insights
into the likelihood of events[9]. We considered an I
2
above 50% as moderate to large heterogeneity and
examined explanations of heterogeneity by applying a
random effects meta-regression with the following
co-variates: oropharyngeal formulation vs. skin patch;
duration of study (in months); reporting of allocation
concealment, and reporting of blinding status. We then
calculated the residual heterogeneity and present it as
the residual I
2. Forest plots are displayed for each pri-
mary analysis, showing pooled study effect measures
with 95% CIs, and the overall DerSimonian-Laird pooled
estimate. For studies considered as observational studies,
we calculated pooled weighted proportions by first stabi-
lizing the variances of the raw proportions (r/n) using a
Freeman-Tukey type arcsine square root transformation
and applying a random effects model. While several
methods of pooling proportions exist, the Freeman-
Tukey method works well with both fixed and random
effects meta-analysis and truncates at zero[22]. This is a
variance-stabilizing transformation that removes the
dependence of the variance on the mean of the trans-
formed proportion (ie. it corrects for overdispersion).
Assessing heterogeneity in pooled proportions may be
misleading[23,24], therefore we report the I
2 value, as
this measure is less affected by the number of studies as
the more commonly used I
2. The square root of this
number (i.e. tau [τ]) is the estimated standard deviation
of underlying effects across studies[25]. As with the
RCT analysis, we applied a random-effects meta-analy-
sis. Analyses were conducted using StatsDirect (version
2.5.2) and Comprehensive Meta-analysis (version 2).
Results
Study inclusion and methods reporting (Figure 1)
O n eh u n d r e da n dt w e n t ys t u d i e sm e to u ri n c l u s i o n
criteria (j = 0.91) [26-117,110,118-141]. Figure 1 displays
the search break-down. Additional file 1 and Table 1 pro-
vide study characteristics. Ninety-two studies[26-117]
were RCTs involving 32,185 participants and 28[56,75,
93,110,118-141] were considered as observational studies
involving 145, 205 participants.
Of RCTs, eighty-three [26-34,37-64,66,105-109,65,
67-85,87-90,92-97,99-102,112,114-117,142](83/92) used
a placebo control. Forty-two[39-41,43,45,47-49,51-55,
60,61,64,66,68-72,74-77,81,83,87,89,90,92,93,98,99,102,
103,105-107,112,115] evaluated the nicotine patch; 26
[26-38,42,56,58,79, 88,95,100,101,108,109,113,116,142]
the nicotine gum; 6 [44,50,57,65,73,111]the nicotine
nasal spray; 6[46,62,63,67,78,96] the nicotine inhaler; 4
[80,84,97,114]the nicotine tablet; 1[85] the nicotine
lozenge; and, the remainder (n = 35) evaluated NRT
combination therapies. Duration of treatment ranged
from 1 to 24 months, with varying levels of dosages for
each form of NRT.
Seventy-four RCTs[26-31,33-41,43-65,67-70,72-80,
82-88,92,93,95,96,99-101,103,106-109,114-117] were
conducted in healthy adult populations. An additional 6
[36,66,89,97,105,113] were conducted among populations
with medical and psychiatric co-morbidities (.eg. smoking-
related diseases, chronic diseases, alcoholism, depression),
4[81,98,104,142] among pregnant women, 3[42,71,91]
among hospitalized patients, 3[90,94,111] among adoles-
cents, 1 [102]among postmenopausal women, and 1[112]
among surgical patients. Fifty-nine [27-30,33,36-38,41,42,
45,48-56,58,59,61-63,66,67,71,73,74,76,77,79,81,83,86,89-
92,94,97-102,104-108,111,113-117,142]RCTs included
co-interventions, of which 20[27,36,49-52,54,61,71,79,81,
91,98,100-102,111,114,116,117] provided general counsel-
ing (eg. group counseling or individual counseling), 19
[28,41,53,56,61,63,67,76,85,89,90,92,94,99,104-107,113]
provided behavioural or psychological treatment, 12
[29,30,33,37,42,45,55,62,66,74,86,97] provided varying
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tional sessions, 4[58,59,73,77] provided an additional NRT
and/or placebo, and 1[115] provided rimonabant, an endo-
cannabinoid antagonist used as an appetite suppressant.
Seventeen observational studies[75,93,110,119-124,
126-129,131-133,141] used the nicotine patch; 2 [125,
135] used a nasal spray, 1[129] used the nicotine gum;
and 8 used a combination of NRTs. Duration of
treatment ranged from 4 to 26 weeks, with varying
levels of dosages for each form of NRT. Sixteen
[56,75,93,110,118,122,123,125-127,129,130,132-134,137]
of the observational studies were conducted among
healthy adult populations, 7 [120,121,131,135,138-140]
among mixed healthy and unhealthy adult populations,
2[136,141] among adult populations with medical co-
morbidities, 2[124,128] among adolescent populations,
Figure 1 low-diagram of included studies.
Mills et al. Tobacco Induced Diseases 2010, 8:8
http://www.tobaccoinduceddiseases.com/content/8/1/8
Page 4 of 15T
a
b
l
e
1
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
n
i
c
o
t
i
n
e
r
e
p
l
a
c
e
m
e
n
t
t
h
e
r
a
p
y
(
N
R
T
)
o
b
s
e
r
v
a
t
i
o
n
a
l
s
t
u
d
i
e
s
A
u
t
h
o
r
C
o
u
n
t
r
y
P
a
r
t
i
c
i
p
a
n
t
s
C
i
g
a
r
e
t
t
e
s
p
e
r
d
a
y
*
(
m
e
a
n
,
m
e
d
i
a
n
)
Y
e
a
r
s
S
m
o
k
i
n
g
*
(
m
e
a
n
,
m
e
d
i
a
n
)
I
n
t
e
r
v
e
n
t
i
o
n
D
o
s
a
g
e
(
m
g
)
N
u
m
b
e
r
t
r
e
a
t
e
d
c
o
-
i
n
t
e
r
v
e
n
t
i
o
n
D
u
r
a
t
i
o
n
o
f
t
r
e
a
t
m
e
n
t
H
i
l
l
e
m
a
n
,
1
9
9
4
U
S
A
H
e
a
l
t
h
y
2
6
*
≥
3
P
a
t
c
h
(
f
i
x
e
d
d
o
s
a
g
e
)
2
1
6
9
E
d
u
c
a
t
i
o
n
s
e
s
s
i
o
n
1
2
w
e
e
k
s
P
a
t
c
h
(
t
a
p
e
r
e
d
d
o
s
e
)
7
,
1
4
,
2
1
7
1
O
r
l
e
a
n
s
,
1
9
9
4
U
S
A
O
l
d
e
r
a
d
u
l
t
s
1
7
*
5
0
*
P
a
t
c
h
7
,
1
4
,
2
1
8
7
1
C
o
u
n
s
e
l
i
n
g
1
2
w
e
e
k
s
F
r
e
d
r
i
c
k
s
o
n
,
1
9
9
5
U
S
A
H
e
a
l
t
h
y
>
2
0
2
8
*
P
a
t
c
h
2
2
,
4
4
4
0
C
o
u
n
s
e
l
i
n
g
8
w
e
e
k
s
H
e
r
r
e
r
a
,
1
9
9
5
S
w
e
d
e
n
H
e
a
l
t
h
y
≥
1
0
N
A
G
u
m
2
,
4
1
6
7
B
e
h
a
v
i
o
u
r
a
l
m
o
d
i
f
i
c
a
t
i
o
n
p
r
o
g
r
a
m
3
m
o
n
t
h
s
J
o
r
e
n
b
y
,
1
9
9
5
U
S
A
H
e
a
l
t
h
y
2
7
*
1
P
a
t
c
h
2
2
,
4
4
5
0
4
C
o
u
n
s
e
l
i
n
g
8
w
e
e
k
s
M
a
r
t
i
n
,
1
9
9
5
N
e
w
Z
e
a
l
a
n
d
H
e
a
l
t
h
y
a
n
d
u
n
h
e
a
l
t
h
y
2
6
*
1
0
*
P
a
t
c
h
7
,
1
4
,
2
1
8
0
C
o
u
n
s
e
l
i
n
g
1
2
w
e
e
k
s
S
m
i
t
h
,
1
9
9
5
U
S
A
H
e
a
l
t
h
y
a
n
d
u
n
h
e
a
l
t
h
y
2
6
*
2
0
*
P
a
t
c
h
7
,
1
4
,
2
1
1
1
0
C
o
u
n
s
e
l
i
n
g
1
2
w
e
e
k
s
S
m
i
t
h
,
1
9
9
6
U
S
A
A
d
o
l
e
s
c
e
n
t
2
3
*
2
.
6
*
P
a
t
c
h
1
1
,
2
2
2
2
C
o
u
n
s
e
l
i
n
g
8
w
e
e
k
s
H
u
r
t
,
1
9
9
8
U
S
A
H
e
a
l
t
h
y
2
8
*
2
2
*
N
a
s
a
l
s
p
r
a
y
1
-
2
m
g
/
h
5
0
C
o
u
n
s
e
l
i
n
g
8
w
e
e
k
s
G
o
u
r
l
a
y
,
1
9
9
9
A
u
s
t
r
a
l
i
a
H
e
a
l
t
h
y
≥
1
5
≥
3
P
a
t
c
h
2
1
1
4
8
1
C
o
u
n
s
e
l
i
n
g
1
2
w
e
e
k
s
H
a
y
s
,
1
9
9
9
U
S
A
H
e
a
l
t
h
y
≥
1
5
≥
1
P
a
t
c
h
2
2
3
1
5
N
o
n
e
6
w
e
e
k
s
K
i
l
l
e
n
,
1
9
9
9
U
S
A
H
e
a
l
t
h
y
3
5
*
N
A
P
a
t
c
h
1
5
o
r
2
5
4
0
8
S
e
l
f
-
t
r
e
a
t
m
e
n
t
b
o
o
k
l
e
t
6
w
e
e
k
s
H
u
r
t
,
2
0
0
0
U
S
A
A
d
o
l
e
s
c
e
n
t
2
0
*
>
1
P
a
t
c
h
1
5
1
0
1
C
o
u
n
s
e
l
i
n
g
6
w
e
e
k
s
S
h
i
f
f
m
a
n
,
2
0
0
2
U
S
A
H
e
a
l
t
h
y
2
7
*
2
4
*
P
a
t
c
h
7
,
1
4
,
2
1
2
3
6
7
N
o
n
e
1
2
w
e
e
k
s
2
7
*
2
3
*
G
u
m
2
,
4
2
9
8
1
N
o
n
e
1
2
w
e
e
k
s
C
r
o
g
h
a
n
,
2
0
0
3
U
S
A
H
e
a
l
t
h
y
≥
1
5
≥
1
P
a
t
c
h
,
N
a
s
a
l
s
p
r
a
y
,
P
a
t
c
h
+
N
a
s
a
l
s
p
r
a
y
1
5
m
g
/
p
a
t
c
h
,
0
.
5
m
g
/
s
p
r
a
y
1
3
8
4
B
e
h
a
v
i
o
u
r
a
l
c
o
u
n
s
e
l
i
n
g
6
w
e
e
k
s
H
a
s
f
o
r
d
,
2
0
0
3
G
e
r
m
a
n
y
H
e
a
l
t
h
y
a
n
d
u
n
h
e
a
l
t
h
y
N
A
1
9
*
P
a
t
c
h
7
,
1
4
,
2
1
6
3
3
N
o
n
e
1
2
w
e
e
k
s
C
a
r
p
e
n
t
e
r
,
2
0
0
4
U
S
A
H
e
a
l
t
h
y
≥
1
0
N
A
P
a
t
c
h
7
,
1
4
,
2
1
3
0
0
R
e
d
u
c
t
i
o
n
c
o
u
n
s
e
l
i
n
g
6
w
e
e
k
s
F
i
o
r
e
,
2
0
0
4
U
S
A
H
e
a
l
t
h
y
≥
1
0
N
A
P
a
t
c
h
7
,
1
4
,
2
1
1
8
6
9
W
i
t
h
o
r
w
i
t
h
o
u
t
e
d
u
c
a
t
i
o
n
p
r
o
g
r
a
m
1
0
w
e
e
k
s
L
e
r
m
a
n
,
2
0
0
4
U
S
A
H
e
a
l
t
h
y
≥
1
0
1
P
a
t
c
h
,
N
a
s
a
l
s
p
r
a
y
0
.
5
,
7
-
2
1
3
5
0
C
o
u
n
s
e
l
i
n
g
8
w
e
e
k
s
S
c
h
u
u
r
m
a
n
s
,
2
0
0
4
S
o
u
t
h
A
f
r
i
c
a
H
e
a
l
t
h
y
≥
1
5
≥
3
P
a
t
c
h
N
A
1
8
4
N
o
n
e
1
0
w
e
e
k
s
H
u
g
h
e
s
,
2
0
0
5
U
S
A
H
e
a
l
t
h
y
a
n
d
u
n
h
e
a
l
t
h
y
2
5
*
2
7
*
N
a
s
a
l
s
p
r
a
y
N
A
5
3
5
N
o
n
e
4
w
e
e
k
s
M
a
r
s
h
,
2
0
0
5
C
z
e
c
h
R
e
p
u
b
l
i
c
M
e
d
i
c
a
l
i
l
l
n
e
s
s
2
5
*
≥
1
G
u
m
,
L
o
z
e
n
g
e
4
9
0
1
N
o
n
e
1
2
w
e
e
k
s
B
o
l
l
i
g
e
r
,
2
0
0
7
S
o
u
t
h
A
f
r
i
c
a
H
e
a
l
t
h
y
2
3
*
2
3
*
G
u
m
,
P
a
t
c
h
,
N
a
s
a
l
s
p
r
a
y
N
A
1
0
0
B
e
h
a
v
i
o
u
r
a
l
c
o
u
n
s
e
l
i
n
g
3
m
o
n
t
h
s
A
u
b
i
n
,
2
0
0
8
U
S
A
H
e
a
l
t
h
y
2
3
*
2
5
*
P
a
t
c
h
7
,
1
4
,
2
1
3
7
0
C
o
u
n
s
e
l
i
n
g
1
0
w
e
e
k
s
S
t
a
p
l
e
t
o
n
,
2
0
0
8
U
K
H
e
a
l
t
h
y
a
n
d
u
n
h
e
a
l
t
h
y
2
1
*
N
A
N
R
T
N
A
2
0
4
E
d
u
c
a
t
i
o
n
s
e
s
s
i
o
n
1
2
w
e
e
k
s
G
u
n
n
e
l
l
,
2
0
0
9
E
u
r
o
p
e
H
e
a
l
t
h
y
a
n
d
u
n
h
e
a
l
t
h
y
N
A
N
A
N
R
T
N
A
6
3
2
6
5
N
o
n
e
1
2
-
2
6
w
e
e
k
s
O
s
s
i
p
,
2
0
0
9
U
S
A
H
e
a
l
t
h
y
a
n
d
u
n
h
e
a
l
t
h
y
N
A
N
A
G
u
m
,
P
a
t
c
h
,
L
o
z
e
n
g
e
2
,
7
-
2
1
,
2
6
5
5
9
9
N
o
n
e
2
w
e
e
k
s
S
t
e
i
n
b
e
r
g
,
2
0
0
9
U
S
A
M
e
d
i
c
a
l
i
l
l
n
e
s
s
e
s
>
1
0
>
2
0
P
a
t
c
h
7
,
1
4
,
2
1
6
4
N
o
n
e
1
0
w
e
e
k
s
Mills et al. Tobacco Induced Diseases 2010, 8:8
http://www.tobaccoinduceddiseases.com/content/8/1/8
Page 5 of 15and 1[119] among an older adult population. The
majority of observational studies[110,119-126,128,
133,134,56,118,127,130,132,137,138](19/28) included
co-interventions, with 12[110,119-126,128,133,134]
providing general counseling; 3[56,130,137] providing
counseling specific to behaviour or behaviour modifica-
tion; 3[118,132,138] providing educational sessions;
and 1 [127]providing a self-help booklet.
Studies reported methodological issues variably. Thirty-
eight RCTs[28,29,31,37,41,44,46,59,61-63,65,70-75,77,78,
81,82,84,85,90,93,97-99,101,102,104,105,112,115-117,142]
reported sequence generation of randomization; 17
[28,29,31,37,59,63,67,69,71,73-75,81,93,98,99,115] reported
allocation concealment; and, 81[26-34,37-64,66,105-
107,109,65,67-80,82-85,87-90,92-97,99-102,112,114-117,
142] reported on patient blinding in the study. To confirm
smoking abstinence, eighty four[26-28,30-46,48-64,
66,105,107-109,65,67,69-80,83-98,100-104,111,112,114-
117,142] studies used exhaled carbon monoxide (CO); 16
[34,35,37,41,45,55,57,62,63,79,81,90,94,107,111,142] used
salivary cotinine; 5[29,36,47,60,101] used serum cotinine;
and 2[99,114] used urinary cotinine. No studies required
participants to pay for the NRT. In 80 studies, [26-29,31-
41,43-54,56-64,66,105-109,113,65,67,68,70-72,74-77,79,
80,83-87,89,90,92-94,97-104,111,112,114-117,142] partici-
pants were planning on quitting. All observational studies
are considered as non-comparative single-arm studies
reporting prevalence of the adverse events in the
community.
Adverse events
RCTs (See Figure 2)
We evaluated all forms of NRT for adverse events.
Additional file 1 displays the study characteristics and
table 2 displays the RCT findings.
Cardiovascular and respiratory
A pooled analysis of 12 RCTs found a statistically signifi-
cant increased risk for heart palpitations and chest pains
associated with NRT (OR 2.06, 95% CI, 1.51-2.82, p <
0.001; I
2 = 0%). Applying meta-regression, both the
nicotine patch and orally administered NRT were asso-
ciated with an increased risk (OR 1.11, 95% CI, 0.53-2.33,
Figure 2 Summary pooled estimates of adverse events reported in RCTs
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Page 7 of 15P = 0.75). Coughing was significantly elevated in 12 RCTs
(OR 2.89, 95% CI, 1.92-4.33, P =< 0.001; I
2 = 72%), but
was associated with considerable heterogeneity.
Gastrointestinal
There was a statistically significant increased risk of
nausea or vomiting based on a pooled analysis of 31
RCTs (OR 1.67, 95% CI, 1.37-2.04, P =< 0.001; I
2 =
62%). However, meta-regression showed that studies
focusing on the nicotine patch were associated with a
decreased risk (OR, 0.73, 95%, 0.56-0.97, P = 0.029) of
nausea and vomiting. The review also found an
increased risk of indigestion and general GI complaints
with NRT in an analysis of 26 RCTs (OR 1.54, 95% CI
1.25-1.89, p < 0.001; I
2 = 35%). Using only orally admi-
nistered NRT caused significantly greater risk for GI
complaints compared with the nicotine patch (OR 1.66,
95% CI, 1.04-2.63, P = 0.03), and was also associated
with an increased risk of hiccoughs (see Table 2).
Oral
A significantly heightened risk of oral adverse events
including mouth and throat soreness was identified in a
meta-analysis of 23 RCTs (OR 1.87, 95% CI, 1.36-2.57,
P < 0.001; I
2 = 66%). A meta-analysis of 6 RCTs found a
significantly elevated risk for mouth ulcers (OR 1.49,
95% CI, 1.05-2.20, P = 0.02; I
2 = 43%).
Neurological
A meta-analysis of 32 RCTs (Table 2) found that head-
ache was not associated with NRT use (P = 0.65; I
2 =
43%), while an analysis of 24 RCTs, found no association
between NRT use and increased dizziness (P = 0.59;
I
2 = 18%)
Dermatological
Nicotine patch was associated with a statistically signifi-
cant risk of skin irritation in an analysis of 32 RCTs
(OR 2.80, 95% CI, 2.28-3.44, P < 0.001; I
2 =0 % ) .H o w -
ever, nicotine patch was not associated with increased
incidence of urticaria (OR 1.13, 95% CI, 0.77-1.65, P =
0.52; I
2 = 0%) or sweating (OR 1.29, 95% CI, 0.51-3.21,
P = 0.58; I
2 = 76%).
Psychological
An increased risk of insomnia was associated with the
nicotine patch (OR 1.42, 95% CI, 1.21-1.66, P < 0.001; I
2
= 65%). Anxiety and depression were, however, not sig-
nificantly increased (see Table 2).
Serious Adverse Events
Twenty five RCTs[47,54,71,73-77,79,80,82,84,85,91-
93,97,98,100,102,104,105,113,115,142] reported serious
adverse events occurring, but none were statistically sig-
nificant (data not shown). Eight studies[73,82,85,93,97,
105,113,115] reported on mortality by groups and did
not find a significant association between NRT and con-
trols. One study[142] of pregnant women found two
cases of spontaneous abortions in the NRT group and
one study[76] reported a case of spinal meningitis in the
NRT group.
Explanations of heterogeneity
We used meta-regression to explain heterogeneity. We
found large heterogeneity (I
2 = 62%) in our analysis of
pooled events of nausea and vomiting. We were able to
explain a large amount of heterogeneity examining the
covariate of skin patch vs. oropharyngeal administration
(OR 0.73, 95% CI, 0.56-0.97, P = 0.02, I
2 = 42%) as well
as reporting of allocation concealment (OR 1.50, 95%
CI, 1.07-1.59, P = 0.002, I
2 = 37%). We also found large
heterogeneity (I
2 = 66%) in the event of mouth and
throat soreness, but were unable to explain this using
our pre-specified covariates. Considerable heterogeneity
(I
2 = 72%) was also identified for the adverse event of
coughing. We found that duration of study (B coeffi-
cient 0.07, 95% CI, 0.01-0.12, P = 0.01, I
2 = 42%) and
allocation concealment (OR 0.53, 95% CI, 0.31-0.91, P =
0.02, I
2 = 43%) contributed to heterogeneity observed in
this analysis. Our analysis of sweating found large het-
erogeneity (76%) that was predominantly contributed by
a study that provided concomitant bupropion, indicating
that the dual use of both drugs resulted in a significantly
higher incidence of sweating (OR 29.24, 95% CI, 3.96-
215.48). We also found heterogeneity in our analysis of
insomnia that was explained by the duration of the
trials. Longer duration trials had reduced rates of insom-
nia (B coefficient -0.07, 95% CI, -0.13 to -0.008, p =
0.02).
Observational studies (See Figure 3)
Table 1 displays the study characteristics of the observa-
tional studies. No studies compared NRT with an inert
control group, thus we present the proportions of event
occurrence, interpreted as prevalence. As our analysis
uses pooled proportions, all analyses found an estimate
of risk, but varied in magnitude. Table 3 presents the
study findings.
Cardiovascular or respiratory
T h ep r e v a l e n c eo fh e a r tp a l p itations and chest pains
were reported sporadically and amounted to 3.6% of the
populations examined. Coughing was reported as a pre-
valence of 8.1%.
Gastrointestinal
In keeping with the RCT evidence indicating significant
increases in specific events, the pooled observational evi-
dence reported the nausea and vomiting prevalence to
be 8.5% amongst individuals in the community treated
with NRT. The prevalence of indigestion and other gas-
trointestinal complaints was 3.9%. Hiccoughs were a
very common complaint in the RCT evidence, but
poorly reported in the observational studies with a pre-
valence of just 2.5%.
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Page 8 of 15Figure 3 Summary pooled estimates of adverse events reported in observational studies.
Table 3 Adverse events reported in observational studies
Adverse event Number
of studies
References N of events Pooled n Proportion 95% CI τ
2
Headache 17 [75,93,110,118-120,123-125,127-129,131,136,138,140,141] 1472 75764 9.7 4.6-19.5 2.97
Nausea or
vomiting
14 [75,110,119,120,123,124,128,129,136-138,140,141] 1902 74449 8.5 4.6-15.3 1.39
Gastrointestinal
complaints
11 [110,118,120,123,127,129,131,136,138,140,141] 593 74256 3.9 1.4-10.4 3.02
Heart
palpitations
7 [75,120,122,127,131,136,141] 72 2446 3.6 1.4-9.0 1.49
Mouth and
throat soreness
6 [125,129,135-137,140] 406 72533 5.4 0.9-25.6 5.00
Skin irritation 16 [75,93,118-124,126-129,131,138,141] 1337 10356 19.5 11.5-31.1 1.56
Hiccoughs 4 [129,136,137,140] 375 71948 2.5 0.3-16.5 4.63
Coughing 5 [120,125,128,135,136] 125 1672 8.1 2.1-26 2.29
Depression 6 [110,120,124,138,140,141] 69 66344 2.6 0.2-27 10.57
Anxiety 5 [118,120,129,138,141] 104 5841 2.9 0.8-9.8 1.70
Insomnia 18 [75,110,118-123,125-129,131,138,140,141] 2262 76169 11.4 4.8-24.6 4.05
Dizziness 8 [110,118,120,124,127,129,136,141] 299 7338 7.3 3.7-13.9 0.94
Self-harm 1 [110,118,120,124,127,129,136,141] 141 63265 0.2 0-8.4 NA
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With orally administered NRT ,t h ep r e v a l e n c eo fb o t h
mouth and throat soreness was 5.4%.
Psychological and neurological
For psychological complaints, the prevalence of insom-
nia was 11.4%. Anxiety and depression were more rarely
reported (2.9% and 2.6% respectively). Dizziness was a
more common complaint, with a prevalence of 7.3%.
Headaches were commonly reported (9.7%).
Dermatological
The prevalence of skin irritations associated with nico-
tine patch was reported as 19.5% of the populations
examined.
Serious adverse events
Serious adverse events were poorly reported in the
observational studies. However, one study reported on a
case of transient visual field impairment; one right-
hemisphere stroke; one myocardial infraction; and one
urticarial reaction from skin patch with symptoms of
angiodema. Finally, in a single large observational study
of self-harm (n = 63,265), 141 cases of fatal and non-
fatal self-harm cases were identified (0.2%), in addition
to 30 cases of suicidal ideation[139].
Discussion
Principal Findings
This review found that NRT is associated with an
increased risk of gastrointestinal complaints and insom-
nia. There was also an observed increased risk of skin
irritation with the nicotine patch and oropharyngeal
complaints with orally administered NRT. Although
NRT was associated with an increased risk of heart pal-
pitations, the review did not observe an increased inci-
dent of heart attack or death. With the exception of
insomnia, NRT does not appear to be associated with
serious adverse psychiatric effects.
The reviewers actively sought serious adverse events.
The most serious adverse event consistently reported in
both RCTs and observational studies were heart palpita-
tions and chest pains (OR 2.06, 95% CI, 1.51-2.82, P <
0.001). NRT has been implicated in reports of atrial
fibrillation and myocardial infarction among patients
with risk factors[143-148]. Several possible explanations
for this exist. First, among patients using NRT who con-
tinue to smoke, high serum concentrations may stimu-
late the sympathetic nervous system, so increasing blood
pressure, stroke volume and cardiac output[149]. Sec-
ond, previous and current smokers may have established
cardiovascular disease. Patients with unstable coronary
syndrome, a common manifestation of coronary artery
disease, may have unrecognized recent plaque ruptures
including coronary vasoconstriction and increased strain
placed on the heart due to tachycardia and hypertension
[143]. Unofficial guidelines[149] caution the continued
use of NRT in patients with known cardiovascular
disease in the absence of a physician. They recommend
that patients be warned of these risks and counseled to
desist smoking and arrange intensive behavioral support
[149]. In our analysis, we did not observe an increased
risk for myocardial infarction or death from NRT.
Almost all studies demonstrated localized irritation
related to NRT use, skin irritation with the use of NRT
patch and mouth soreness and ulcerations with orally
administered NRT. It is possible this is due to the suc-
cess of cessation rather than NRT as mouth ulcers
occur in about 40% of all individuals achieving tobacco
abstinence regardless of cessation intervention[150]. It
has previously been understood that mouth lesions are
associated with smoking cessation and not NRT[150].
However, this review found a significantly increased risk
of mouth ulcers with orally administered NRT users
compared to inert controls who had ceased smoking. In
order to prevent relapse due to treatment discontinua-
tion, strategies should be developed to assist patients
unable to continue oral administered NRT due to
mouth ulcers such as increasing the nicotine patch dose,
using the nicotine nasal spray, or switching to an alter-
native form of smoking cessation pharmacotherapy such
as buproprion or varenicline.
Psychological adverse events, particularly suicidal idea-
tion, are a major concern in patients initiating smoking
cessation[151]. We found only one large retrospective
observational study that discussed this topic and
reported no significant difference in fatal and non-fatal
self-harm associated with NRT compared to other fre-
quently used pharmacotherapies, bupropion (HR 1.17,
95% CI, 0.59-2.32) or varenicline (HR 1.12, 95% CI,
0.67-1.88)[139].
A criticism of smoking cessation trials has been that
they infrequently enroll participants with psychological
difficulties, thus making generalizable statements about
their safety difficult[152]. The present review found that
56 RCTs specifically excluded participants with mental
disorders. Only two RCTs targeting participants with
concomitant psychological difficulties, specifically alco-
holism and depression, were identified[89,92]. In these
studies, the risk of insomnia was higher among those
taking NRT, compared to controls, (OR 1.42, 95% CI,
1.21-1.66, P < 0.001). Sleep disturbance can significantly
worsen psychological distress and mental illness and
impair quality of life[153]. Therefore, clinicians should
remain vigilant about NRT-related sleep disturbance
among patients with a history of psychiatric illness.
An important issue to examine when describing
adverse events from smoking cessation therapies is
whether the adverse events are related to a pharma-
cotherapy or whether they are related to tobacco
withdrawal[154]. For example, insomnia and sleep
Mills et al. Tobacco Induced Diseases 2010, 8:8
http://www.tobaccoinduceddiseases.com/content/8/1/8
Page 10 of 15disturbances could be related to tobacco abstinence.
One way to assess this affect would be to compare side
effects in those that have quit smoking in both groups.
However, since individuals that quit smoking may differ
from those that continue, this analysis would remove
the benefits of randomization and introduce bias.
Limitations
Our review has several limitations. These include limita-
tions of the primary studies themselves as well as those
associated with combining results across potentially het-
erogeneous studies or populations. The main limitation
of the primary studies is the mechanism by which
adverse events are recorded. In the majority of instances
this would be through passive reporting and therefore
be susceptible to the underreporting associated with
such techniques. The majority of our analyses had low
or moderate heterogeneity, although a few had high
levels of heterogeneity. Pooling proportions always
results in large estimates of heterogeneity and statistical
techniques do not yet exist to interpret the extent of
real between-study heterogeneity[155]. The review iden-
tified some discrepancies between observational studies
and RCTs in terms of adverse event reporting. Possible
explanations of this include the use of a control group
in the RCTs, which diminishes the impact of adverse
events that are, in fact, unrelated to the intervention.
Studies included in our review varied in the duration of
treatment phase. While we would expect most adverse
events to occur during the treatment phase (receiving
active NRT), it is possible that some adverse events
occurred during follow-up and we cannot adequately
explain their pathological processes.
There is emerging evidence that stopping smoking
prior to any type of surgery decreases the potential for
surgical complications[156]. All pharmacotherapies used
for smoking cessation demonstrate adverse events, albeit
in differing conditions and severity[4]. However, given
the cardiovascular concerns discussed above, and the
fact that cardiovascular events are increased during the
perioperative period[157], it is reasonable to consider
other behavioral or pharmacotherapies for at-risk
patients undergoing major surgeries.
Conclusions
This review demonstrates that NRT is associated with
adverse effects that may be discomforting for the patient
but are not life-threatening. Given the long-term bene-
fits of smoking cessation over continued smoking, con-
cern about NRT related adverse events should be
balanced against the benefits of cessation. Clinicians
should monitor for side effects that may worsen under-
lying conditions, such as insomnia in patients with
depression, and consider additional or alternative
treatments. Given the benefits of smoking cessation and
the important role of NRT in achieving this goal, efforts
should be made to counsel patients on the most com-
mon side effects and strategies should be developed to
deal with them.
Additional material
Additional file 1: Characteristics of included RCTs. CVD,
cardiovascular; RCT, randomized clinical trial
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